Table 2 Clinical-laboratory characteristics and therapeutic modalities in 93 ENKTL patients categorized by response to up-front treatment.
Characteristic | Non-R/R (N = 53) | Refractory (N = 19) | Relapsed (N = 21) | p-value |
|---|---|---|---|---|
Age ≥ 60 years | 13 (24.5%) | 3 (15.8%) | 3 (14.3%) | 0.516 |
Extranasal disease | 6 (11.3%) | 4 (21.1%) | 3 (14.3%) | 0.597 |
CS III/IV | 15 (28.3%) | 9 (47.4%) | 6 (28.6%) | 0.303 |
ECOG ≥ 2 | 16 (30.2%) | 5 (26.3%) | 3 (14.3%) | 0.369 |
PINK high-risk | 13 (24.5%) | 10 (52.6%) | 4 (19.0%) | 0.035 |
B-Symptoms | 35 (66.0%) | 13 (68.4%) | 11 (52.4%) | 0.480 |
Bulky ≥ 7 cm | 1 (1.8%) | 2 (10.5%) | 3 (14.3%) | 0.106 |
Nasal infection | 21 (39.6%) | 17(89.4%) | 11 (52.3%) | < 0.001 |
Hb < 120 g/L | 23 (43.4%) | 9 (47.3%) | 9 (42.8%) | 0.948 |
Leukopenia | 11 (20.7%) | 6 (31.6%) | 5 (23.8%) | 0.635 |
Neutropenia | 2 (3.8%) | 1 (5.2%) | 1 (4.8%) | 0.956 |
Lymphopenia | 20 (37.8%) | 10 (52.6%) | 4 (19.0%) | 0.085 |
Thrombocytopenia | 7 (13.2%) | 3 (14.2%) | 1 (4.8%) | 0.499 |
Albumin < 3.5 g/dL | 17/44 (38.6%) | 9/15 (60.0%) | 5/14 (35.7%) | 0.299 |
EBV-DNA positivity | 26/39 (66.7%) | 8/14 (57.1%) | 10/12 (83.3%) | 0.354 |
No EF-RT | 21 (39.6%) | 13 (68.4%) | 3 (14.3%) | 0.002 |
Chemo-regimen | ||||
CCRT/VIPD | 11/48 (22.9%) | 5/16 (31.3%) | 5/20 (25.0%) | 0.963 |
Asparaginase | 18/48 (37.5%) | 6/16 (37.5%) | 7/20 (35.0%) | |
CHOP-like | 19/48 (39.6%) | 5/16 (31.3%) | 8/20 (40.0%) | |
